Of late, anemia drug administration has become a hot potato, particularly when Medicare announced that it would not cover use of anemia medications in some situations. Now, a pair of U.S. Representatives have introduced a resolution which would forcibly change CMS's policy.
Medicare said in July that it would cover use of Aranesp and Procrit when a patient had anemia caused by chemotherapy, but not when the anemia was caused by cancer. The move upset many House members, 250 of whom signed a letter sent to CMS last year arguing that the decision would inappropriately cause more cancer patients to undergo blood transfusions.
To learn more about the bill:
- read this Kaiser Daily Health Policy Report item
Related Articles:
Dialysis firms defend anemia drug use along ethnic lines. Report
FDA group recommends anemia drug limits. Report
Anemia drug rebates challenged. Report
Regulators question anemia drugs. Report
New study points to danger of anemia drug. Report